Alex's Lemonade Stand Foundation
Alex’s Lemonade Stand Foundation (ALSF) generously supports the COG/ALSF Childhood Cancer Repository that establishes cell lines and patient-derived xenografts from childhood cancers and provides these laboratory models to > 600 laboratories in 26 countries.
CerRx, Inc. is carrying out commercial development of fenretinide and fenretinide-based drug combinations in collaboration with Cancer Center investigators via grant support from CPRIT and the NCI.
Laura W. Bush Institute for Women's Health
The Laura W. Bush Institute for Women's Health partners with the Cancer Center in delivery of cancer prevention services to the South Plains region and in cancer biobanking.
Texas Cancer Cell Repository (TXCCR)
The TXCCR is a consortium of translational laboratory investigators that collaborate to establish, bank, and distribute cancers grown in the laboratory and in special mice that will serve as models to study the biology of cancer and to develop novel approaches to therapy.
The Children's Oncology Group
The Children's Oncology Group (COG) is the national organization of > 200 institutions that carries our research in childhood cancer.
The New Approaches to Neuroblastoma Therapy Consortium
The New Approaches to Neuroblastoma Therapy (NANT) consortium is a clinical consortium of ~ 14 academic institutions that conduct early phase clinical trials testing new therapies for recurrent neuroblastoma, a childhood cancer.
The South Plains Oncology Consortium
The South Plains Oncology Consortium (SPOC) is a consortium funded by the State of Texas to carry out research on new anti-cancer drugs. Members of SPOC include TTUHSC School of Medicine, Covenant Medical Center (Lubbock), MD Anderson Cancer Institute (Houston), University of Oklahoma (Oklahoma City), and UT Southwestern Medical Center (Dallas). SPOC also conducts trials in collaboration with the California Cancer Consortium and the National Cancer Institute.
Cancer Center investigators are working with United Therapeutics Corporation to assess the relationship of GD2 antigen density and response to chemoimmunotherapy of neuroblastoma.